文献速递抗栓抗凝管理特殊人群用药

儿童心胸外科术后低剂量华法林预防性给药的剂量与安全性评价

Evaluation of dosing and safety outcomes of low-dose prophylactic warfarin in children after cardiothoracic surgery.
PubMed 文献 · Am J Health Syst Pharm · 2020-01-01

本研究回顾性分析了26例18岁及以下心胸外科术后接受华法林预防性抗凝(INR目标1.5–2.0)的患儿,中位初始剂量为0.07 mg/kg/d(IQR 0.05–0.10),低于文献推荐的0.1 mg/kg/d。尽管起始剂量较低,69.2%的患儿在研究期间至少出现一次INR超治疗范围,多发生在用药第2–4天,出院时仅42.3%达标,30天再入院率15.4%(其中2例记录出血)。提示术后儿童起始华法林剂量宜低于0.1 mg/kg/d并加强INR监测。

要点

  • 心胸外科术后儿童华法林中位初始剂量为0.07 mg/kg/d(IQR 0.05–0.10),低于推荐的0.1 mg/kg/d。
  • 69.2%患儿至少一次INR超治疗范围,多见于用药第2–4天。
  • 出院时仅42.3%患儿INR达标,30天再入院率15.4%。

核心结论

  • 多数患儿接受的初始华法林剂量低于已发表推荐剂量,但研究期间仍至少一次出现INR超治疗范围。
  • 心胸外科术后起始华法林时,可能需要低于0.1 mg/kg/d的剂量并频繁监测以达到INR 1.5–2.0的目标。

研究设计与样本

  • 主要目标为确定中位初始华法林剂量,次要目标包括INR超治疗范围比例、出院时达标比例及30天再入院率。

主要发现

  • 中位初始华法林剂量为0.07 mg/kg/d(IQR 0.05–0.10 mg/kg/d)。
  • 研究期间共收集177个INR值,其中67个(37.9%)达标、64个(36.2%)低于治疗范围、46个(26.0%)超治疗范围。
  • 18例(69.2%)患儿在研究期间至少一次INR超治疗范围,最常出现在治疗第2–4天。
  • 出院时11例(42.3%)患儿INR达标。
  • 4例(15.4%)患儿在30天内再入院,其中2例再入院期间记录有出血。

关键数值与推荐

  • 预防性华法林INR目标为1.5–2.0。
  • 已发表文献建议剂量为0.1 mg/kg/d以达上述目标。
  • 本研究观察到中位初始剂量0.07 mg/kg/d(IQR 0.05–0.10 mg/kg/d)。
  • 研究期间INR达标率37.9%(67/177),低于治疗范围36.2%(64/177),超治疗范围26.0%(46/177)。

临床怎么用

  • 心胸外科术后儿童启动华法林时,可考虑初始剂量低于0.1 mg/kg/d。
  • 用药第2–4天应加强INR监测,以及时发现超治疗范围。
  • 出院前需确认INR达标,并关注30天内再入院及出血风险。

局限性

  • 回顾性、描述性研究,样本量仅26例。
  • 单中心研究,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Prophylactic warfarin with an International Normalized Ratio (INR) goal of 1.5 to 2.0 is one antithrombotic therapy utilized in children after cardiothoracic surgery (CTS); published sources suggest a dose of 0.1 mg/kg per day to achieve this goal. However, few studies have evaluated dosing in this population. The purpose of this study was to evaluate dosing and safety outcomes in children receiving warfarin after CTS. METHODS: A descriptive, retrospective review was conducted to evaluate warfarin dosing and INR outcomes in patients 18 years of age or younger who underwent CTS and received prophylactic warfarin with an INR goal of 1.5 to 2.0 from January 2014 through December 2018. The primary objective was to determine the median initial warfarin dose. Secondary objectives included identifying the percentage of documented INR values that were outside the therapeutic range, the percentage of patients with therapeutic INRs at discharge, and the 30-day readmission rate. RESULTS: Twenty-six patients were included in the review. The median initial warfarin dosage was 0.07 mg/kg/d (interquartile range [IQR], 0.05-0.10 mg/kg/d). Of the total of 177 INR values collected during the entire study period, 67 (37.9%) were therapeutic, 64 (36.2%) were subtherapeutic, and 46 (26.0%) were supratherapeutic. Eighteen patients (69.2%) had at least 1 supratherapeutic INR at any point during the study period, most frequently on days 2 through 4 of therapy. At discharge, 11 patients (42.3%) had therapeutic INRs. Four patients (15.4%) were readmitted within 30 days, with bleeding documented in 2 patients during their readmission. CONCLUSION: The majority of patients received an initial warfarin dose less than that specified in published recommendations but still had a supratherapeutic INR at least once during the study period. When initiating warfarin after CTS, a dosage of <0.1 mg/kg per day and frequent monitoring may be needed to achieve an INR goal of 1.5 to 2.0.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Harkin M, Shaddix BP, Neely SB, et al. Evaluation of dosing and safety outcomes of low-dose prophylactic warfarin in children after cardiothoracic surgery. Am J Health Syst Pharm. 2020. PMID: 32470108. doi:10.1093/ajhp/zxaa111

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。